Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine

The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. A phase IIa safety and immunogenicity trial was undertaken in Dunedin, New Zealand between January 2012 and April 2014. Healthy, full-term (≥ 36 weeks gestation) babies, who were 0–5 d ol...

全面介紹

書目詳細資料
Main Authors: Daniel Cowley, Karen Boniface, Nada Bogdanovic-Sakran, Carl D. Kirkwood, Julie E. Bines
格式: Article
語言:English
出版: Taylor & Francis Group 2017-08-01
叢編:Human Vaccines & Immunotherapeutics
主題:
在線閱讀:http://dx.doi.org/10.1080/21645515.2017.1323591

相似書籍